跳至主要内容
临床试验/NCT01284712
NCT01284712Unknown不适用

Natural Killer Cells and Polycythemia Vera (Vaquez's Disease)

Assistance Publique Hopitaux De Marseille1 个研究点 分布在 1 个国家目标入组 27 人开始时间: 2009年7月最近更新:
适应症

试验速览

阶段
不适用
入组人数
27
试验地点
1
主要终点
To describe immunologic anomalies in polycythemia vera

研究概览

简要总结

Natural Killer cells (NK) are pivotal cells of innate immunity, that sense defective expression of HLA class I molecules and are complementary to specific cytotoxic T lymphocytes. A defect in NK cell cytotoxicity has been described in some hematopoietic malignancies such as acute myeloid leukemia, multiple myeloma, myelodysplastic syndroms. This defect is at least partially linked to a decreased or absent expression of some activating NK cell molecules, more particularly the so-called Natural Cytotoxicity Receptors (NCRs) NKp30, NKp44 and NKp46. Some old publications have demonstrated defective NK cytotoxicity in myeloproliferative syndroms (chronic myeloid leukemia, primary thrombocytosis, polycythemia vera). The investigators more particularly focused their attention on polycythemia vera (Vaquez's disease), a myeloproliferative disease characterized by the recently describet mutation V617F of the JAK2 tyrosine kinase. The investigators will precise the mechanisms leading to this cytotoxicity defect, the investigators also will evaluate the implication of V617F mutation on NK physiology, and will study the interactions between NK cells and hematopoietic progenitors.

研究设计

研究类型
Observational
时间视角
Prospective

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Polycythemia vera
  • Treatment by therapeutic bleedings
  • No cytotoxic treatment during the previous six months

排除标准

  • No Polycythemia vera
  • No treatment by therapeutic bleedings
  • Cytotoxic treatment during the previous six months

结局指标

主要结局

To describe immunologic anomalies in polycythemia vera

时间窗: 2 years

次要结局

未报告次要终点

研究者

申办方类型
Other
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验